EGFR and non-small cell lung carcinoma: In the past decade, much attention has been paid to identifying a number of oncogenic driver mutations in NSCLC, including constitutive activation mutations within the epidermal growth factor receptor (EGFR) (Jackman et al., 2006; Rosell et al., 2009) or anaplastic lymphoma kinase (ALK) rearrangement (Soda et al., 2007).